A Research Registry on Aggressive PitNETs

To allow the identification of markers, it is necessary to extend research networks more widely to collect and properly explore aggressive pituitary tumours. The multidisciplinary consultation meeting (RCP), organised by the reference centre for rare diseases of the pituitary gland, dedicated to aggressive pituitary tumours and carcinomas (HYPOcare), which is unique in France and brings together national experts, currently makes it possible to orientate the management of patients with an aggressive pituitary tumour. With more than 80 patient files discussed since its inception, the patient cohort via the HYPOcare RCP is one of the largest both nationally and internationally. At present, this data source is only dedicated to the clinical management of the files without the possibility of carrying out research work

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Endocrine Tumor Disease Attributes Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Site Pathologic Processes Pathological Conditions, Signs and Symptoms Rare Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospices Civils de Lyon - Groupement Hospitalier Est

Lyon, 69003, France

Location status: Recruiting

Location contact

Gérald RAVEROT, PhD - MD

CONTACT

[email protected]

4 72 11 93 25 ext. +33

Gérald RAVEROT, PhD - MD

PRINCIPAL_INVESTIGATOR

Laurent VILLENEUVE

CONTACT

[email protected]

4 78 86 45 36 ext. +33

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion Criteria :

Patients with a diagnosis of pituitary tumour
Patients whose file has been presented to the national HYPOcare RCP
Exclusion Criteria :

Patients objecting to participating in this research

Treatment and study plan

Primary outcomes

Characterisation of aggressiveness of pituitary tumours by tanscriptome analysis

Time frame: 3 years

Molecular and transcriptomic signature of aggressiveness of pituitary tumours predictive of prognosis

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: RECAPitNETT

Important dates

Study start: 2023
Primary completion: 2029
Study completion: 2029
First posted: Aug 3, 2023
Registry last updated: Aug 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting